The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

A federal grant for HIV research is part of $15.7 million the National Institutes for Health awarded to the Wertheim UF ...

Cabotegravir was already approved for use in England and Wales as part of a combination treatment for people living with HIV.

The drug can be produced for as little as $25 per person annually, but even at $2000 per person, it can reduce new US infections almost entirely, a researcher says.

As many as 70% of those living with HIV are expected to be 50 or older by 2030. They often need skilled nursing earlier than ...

NanoViricides, Inc. (NYSE American: NNVC ) (the "Company"), a clinical stage leader developing revolutionary broad-spectrum antiviral drugs that the virus cannot escape, announced that it will be ...

A recently approved twice-yearly injection to prevent HIV may warrant a higher price, but thousands of dollars more?  CVS Caremark’s chief medical officer calls on Gilead Sciences to lower the $28,000 ...

Injectable HIV PrEP marks a breakthrough in prevention, providing a new option for patients in England unable to take daily ...

Healio is on-site again for IDWeek, which is being held at the Georgia World Congress Center in Atlanta from Oct. 19 to ...

Intracellular living therapeutics convert cellular signals into coordinated healing programs Get small and look inside. I ...

For most people, medicines are a bottle of pills on a shelf — made by drug companies, stocked by pharmacies, prescribed by doctors. But drugs that people take for serious illnesses — to prevent HIV, ...

No good deed goes unpunished. Gilead Sciences’ stock is proof. It’s time for investors to give the biotech another look. A little more than a decade ago, Gilead introduced Sovaldi and Harvoni, ...